(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 31.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.77%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.86%.
Travere Therapeutics's revenue in 2026 is $536,196,000.On average, 16 Wall Street analysts forecast TVTX's revenue for 2026 to be $66,400,653,886, with the lowest TVTX revenue forecast at $54,224,162,906, and the highest TVTX revenue forecast at $91,891,869,005. On average, 16 Wall Street analysts forecast TVTX's revenue for 2027 to be $92,102,032,970, with the lowest TVTX revenue forecast at $66,071,459,003, and the highest TVTX revenue forecast at $128,702,180,520.
In 2028, TVTX is forecast to generate $111,963,457,620 in revenue, with the lowest revenue forecast at $81,108,411,741 and the highest revenue forecast at $148,602,662,190.